Country Access Report
Indonesia permits licensed medical use of ketamine (as an approved anesthetic) and has a registered esketamine product (Spravato) with BPOM marketing authorization; both are available only through regulated medical channels and are not routinely reimbursed by public insurance for psychiatric indications. All classical psychedelic compounds requested (psilocybin, MDMA, DMT, 5-MeO-DMT, ayahuasca, mescaline, 2C‑X) are controlled or treated as illegal under Indonesian narcotics/psikotropika regulation and enforcement, with no routine medical reimbursement pathways except within approved clinical research or where a narrowly applicable regulatory exception exists. Ibogaine/iboga occupy a more ambiguous/legal‑gray status in many jurisdictions globally and in Indonesia there is limited public evidence of an authorized medical pathway; therefore access is effectively nonexistent outside informal/underground settings or research contexts.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Currently classified and enforced by Indonesian authorities as a prohibited narcotic/psychedelic (magic mushrooms/psilocybin have been treated as narcotics under Indonesian law and local enforcement), with no authorized medical use or reimbursement outside approved clinical research. Enforcement and court decisions have treated psilocybin-containing mushrooms as narcotics with substantial criminal penalties; possession, sale or distribution is prosecuted. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use or reimbursement outside of approved clinical research; trafficking is heavily penalized (Indonesia enforces stringent criminal penalties for trafficking and large‑quantity possession). High-profile prosecutions and government statements underscore a zero‑tolerance enforcement posture. [1] [2]
Compound Access
Esketamine nasal spray (Spravato) is registered with Indonesia's National Agency of Drug and Food Control (BPOM) and appears on the BPOM product registry with a marketing authorization/assessment record (NIE) — indicating an authorized, regulated medical product presence in the Indonesian market. Access is via prescription/regulated medical channels and is not generally a reimbursed standard therapy under public universal coverage for psychiatric indications; availability will be limited to hospitals/clinics and private providers that supply and administer the product per BPOM and Ministry of Health requirements. Specifics: BPOM’s product registry lists SPRAVATO NASAL SPRAY (esketamine) with an NIE and registration/variation history (initial listing and later labeling/ indication/posology variations), demonstrating formal regulatory approval/registration in Indonesia. Reimbursement: there is no publicly available evidence that esketamine for TRD is included in Indonesia’s national formulary or routinely reimbursed by BPJS Kesehatan; reimbursement would therefore be on a private/clinic basis or exceptional/individual funding arrangements. [1]
Compound Access
Ketamine is an approved and widely used anesthetic/analgesic in Indonesia and appears in national health product registries as an ‘obat keras’ with multiple marketed injectable products registered with BPOM and listed in Ministry of Health procurement/product databases; it is routinely stocked for anesthesia and emergency use in hospitals and clinics. [1] [2]
Regulatory and medical-use nuance: ketamine remains regulated as a prescription (strong) medicine; Indonesian authorities (BPOM and Kemenkes) have flagged concerns about diversion and misuse and in late 2024/early 2025 BPOM publicly indicated intent to propose tighter control or rescheduling of ketamine into a narcotics/psikotropika classification to strengthen controls. That proposed reclassification effort reflects heightened regulatory scrutiny and could change distribution/ prescribing requirements and enforcement in the near term. [3] [4]
Psychiatric/off-label use and reimbursement: while ketamine is used off‑label worldwide for severe depression and acute suicidality, in Indonesia there is no standardized, nationally reimbursed ketamine‑for‑depression program publicly documented; off‑label psychiatric administrations would generally be private/clinic‑based, require clinician oversight, and be subject to hospital/clinic policies. Any practitioner‑led off‑label use should follow Ministry of Health guidance and local institutional approvals; prospective reclassification (if implemented) could further restrict dispensing and require stricter reporting/controls.
Compound Access
Currently classified as a controlled/illegal substance under Indonesian narcotics/psikotropika regulation and related bans on plants/ingredients that contain DMT (authorities have listed chacruna/jurema and related materials among controlled items), with no authorized medical use or market reimbursement outside approved clinical research. Possession, importation or distribution is prosecutable. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use or reimbursement outside of approved clinical research. Indonesian narcotics/psikotropika controls and enforcement treat synthetic and many naturally occurring powerful tryptamines as prohibited materials; there is no regulated medical pathway for 5‑MeO‑DMT treatment or reimbursement. [1] [2]
Compound Access
Iboga/ibogaine are not prominently scheduled under Indonesia’s documented narcotics/psikotropika lists in public sources and some international reviews identify ibogaine as unscheduled in many countries; however, there is no established, authorized medical treatment program or reimbursement pathway in Indonesia for ibogaine, and clinical/medical use is effectively unavailable outside informal/unsanctioned contexts. Due to the absence of a regulated approval, medical provision would face legal and regulatory risks (administrative/criminal) if presented as an unlicensed therapeutic intervention; therefore practical access is effectively nil outside research or underground practice. (Global/regulatory surveys: ibogaine often sits in a legal gray area in many jurisdictions; see NGO and review summaries.) [1] [2] [3]
Compound Access
Ayahuasca (a DMT‑containing brew) is treated under Indonesian narcotics/psikotropika frameworks as containing controlled substances (DMT and MAOI components are regulated/banned); there is no authorized medical use or reimbursement and ceremonial/religious uses have no recognized legal exemption in Indonesia. Events or ceremonies involving ayahuasca have been subject to law enforcement action in countries where DMT is controlled, and Indonesian regulations and enforcement treat ayahuasca‑relevant plant materials among controlled items. [1] [2]
Compound Access
Mescaline is classified as a prohibited narcotic under Indonesian regulations (mescaline‑containing cacti/derivatives are treated under narcotics/psikotropika scheduling), with no authorized medical reimbursement pathway; possession, extraction or distribution is prosecutable. Court and police practice has treated peyote/mescaline analogues as controlled/narcotic items under the law. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws and enforcement practice, with no authorized medical use or reimbursement outside approved clinical research. New psychoactive substances (including various 2C compounds and analogues) are actively monitored and added to Indonesia’s controlled lists when identified, and BNN has emphasized action against NPS proliferation. [1] [2]
Last updated 2 Mar 2026. Source links come from the medical access guide.